Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: J Endocrinol Invest. 2014 Sep 7;37(11):1121–1126. doi: 10.1007/s40618-014-0158-6

Alpha Klotho and phosphate homeostasis (VSports注册入口)

Ao Bian 1,4, Changying Xing 4, Ming Chang Hu (V体育ios版) 1,2,*
PMCID: PMC4485939  NIHMSID: NIHMS701159  PMID: 25194425

Abstract

The Klotho family consists of three single-pass transmembrane proteins—αKlotho, βKlotho and γKlotho. Each of them combines with fibroblast growth factor (FGF) receptors (FGFRs) to form receptor complexes for various FGF’s. αKlotho is a co-receptor for physiological FGF23 signaling and appears essential for FGF23-mediated regulation of mineral metabolism. αKlotho protein also plays a FGF23-independent role in phosphate homeostasis. Animal experimental studies and clinical observations have demonstrated that αKlotho deficiency leads to severe hyperphosphatemia; moderate elevation of αKlotho reduces serum phosphate and extremely high αKlotho induces hypophosphatemia and high-FGF23 VSports最新版本. αKlotho maintains circulating phosphate in a narrow range by modulating intestinal phosphate absorption, urinary phosphate excretion by the kidney, and phosphate distribution into bone rather than soft tissue in concerted interaction with other calciophosphotropic hormones such as PTH, FGF23, and 1,25-(OH)2 vitamin D. The role of αKlotho in maintenance of phosphate homeostasis is mediated by direct suppression of Na-dependent phosphate cotransporters in target organs. Therefore, αKlotho manipulation may be a novel strategy for genetic and acquired phosphate disorders and for medical conditions with αKlotho deficiency such as chronic kidney disease in future.

Keywords: αKlotho, Phosphate homeostasis, Na-dependent phosphate (NaPi) co-transporter, Chronic kidney disease

Introduction

Alpha-Klotho (αKlotho) and fibroblast growth factor23 (FGF23) were independently discovered in 19971 and 20002 and were identified as an anti-aging protein and a novel phosphatonin respectively. Interestingly, the FGF23-null mouse phenocopies almost all features of the αKlotho-null mouse suggesting that αKlotho and FGF23 may share common signaling pathways at least in the maintenance of mineral metabolism3. In vitro experiments further confirmed that membrane αKlotho functions as a mandatory co-receptor for FGF23 along with theFGF receptor (FGFR) to transduce FGF23 signaling to modulate calcium and phosphate metabolism as a calciophosphotropic hormone4, 5 VSports注册入口.

The identification of αKlotho as co-receptor of FGF23 has broadened our understanding of mineral metabolism V体育官网入口. Emerging evidence suggests that αKlotho also act independently of FGf23 as a phosphate regulator. αKlotho contributesto phosphate homeostasis via interplay with other calciophosphoregulatory hormones (parathyroid hormone, FGF23, and 1,25-[OH]2 vitamin D) in the kidney, bone, intestine, and parathyroid gland. αKlotho deficiency triggers and aggravates deranged mineral metabolism, secondary hyperparathyroidism, vascular calcification, cardiac hypertrophy and fibrosis, and kidney fibrosis as evident in chronic kidney disease (CKD) and end-stage renal disease (ESRD). This review will update current understanding of αKlotho, and its contribution to maintenance of phosphate homeostasis. The contributions of αKlotho to aging, acute kidney injury and chronic kidney disease have been recently reviewed6-13.

Overview of phosphate homeostasis

Phosphorus, its element of phosphate, is the 6th most abundant element in the human being. About 1% of body phosphate is present in extracellular fluid. Serum phosphate serves as an exchange pool among various phosphate-regulating organs (kidney, intestine, and bone)9,14 VSports在线直播. Fecal and urine phosphate excretion is a major way to maintain phosphate homeostasis through a complicated, but tightly and efficiently regulated network consisting of several calciophosphoregulatory hormones (PTH, FGF23, 1,25-[OH]2 vitamin D) which are dedicated to both calcium and phosphate regulation15, 16,17.

FGF23, known as a phosphatonin, is predominantly synthesized in osteocytes and osteoblasts12, 18-20. It is regulated by dietary phosphate intake, serum phosphate, 1,25-(OH)2 vitamin D, PTH, and αKlotho, and mainly targets FGFRs through formation of a tertiary complex with membrane αKlotho protein to inhibit renal phosphate reabsorption by decreasing NaPi transport activity and to suppress 1,25-(OH)2 vitamin D production in the kidney21-25. FGF23 also decreases PTH production, which in turn decreases bone turnover12, 26 V体育2025版.

Synthesized by chief cells in parathyroid glands, PTH responses directly to extracellular calcium concentration via calcium-sensing receptor and changes in PTH mRNA stability27,28. PTH acts as phosphaturic hormone, reducing tubular phosphate reabsorption through promoting endocytosis of the Na-coupled phosphate transporters NaPi-2a and 2c in proximal tubular epithelial cells, thus increasing urinary phosphate excretion29-31. PTH also modulates bone turnover, contributing to calcium and phosphate homeostasis of the skeleton32. In early stage of hyperparathyroidism, PTH stimulates bone release of calcium and phosphate, enhances intestinal absorption of calcium and phosphate, and increases renal calcium reabsorption while decreasing urinary phosphate reabsorption, thus maintaining a relatively normal serum phosphate concentration33 VSports. High PTH can stimulate the secretion of 1,25-(OH)2 vitamin D and FGF2312 .

1,25-(OH)2 vitamin D, whose production is suppressed by membrane α-Klotho8, 15, activates intestinal calcium and phosphate absorption. However, active vitamin D stimulates α-Klotho production in the kidney. Independent of changes in intestinal calcium absorption and serum calcium, 1,25-(OH)2 vitamin D represses the transcription of PTH by associating with the vitamin D receptor, decreasing renal excretion of phosphate34. High vitamin D may also decrease FGF23 levels, further limiting phosphate excretion12 VSports app下载.

αKlotho is predominantly expressed in renal distal convoluted tubules with lower abundance in proximal convoluted tubules, and also in parathyroid chief cells, making the kidney and parathyroid gland the primary FGF23 target organs26, 35. FGF23, without the participation of αKlotho, fails to regulate phosphate homeostasis. When 293 cells are co-transfected with a αKlotho and FGFRs, they acquire the ability to respond to FGF23 and activate FGF signaling36. Both FGF23-deficient36 and αKlotho-deficient mice37,1 showed increased serum levels of phosphate and 1,25-(OH)2 vitamin D, which may result from impaired suppression of cyp27b138 and NaPi activity35, 39. Both circulating soluble αKlotho and membrane αKlotho can suppress the secretion of PTH and 1,25-(OH)2 vitamin D, thus indirectly influence the production of FGF238, 15. Whether αKlotho directly modulates FGF23 production in the bone remains to be confirmed.

Taken together, almost all players implicated in phosphate homeostasis are PTH, 1,25(OH)2 vitamin D, FGF23, and αKlotho that regulate phosphate metabolism independently but are also highly interrelated through modulation of other hormones’ metabolism.

Role of abnormal αKlotho in disturbed phosphate metabolism

"V体育官网入口" αKlotho deficiency

The role of αKlotho in phosphate homeostasis was recognized as soon as αKlotho was discovered because the αKlotho-deficient mouse demonstrates severe hyperphosphatemia1. This was further confirmed by the fact that there is low serum phosphate in αKlotho overexpressing mice40. A patient with homozygous missense mutation (H193R) in the αKLOTHO gene had severe calcinosis, dural and carotid artery calcifications, severe hyperphosphatemia, hypercalcemia, and high serum 1,25-(OH)2 vitamin D and FGF2341. This mutation conceivably destabilizes KL1 domain of αKlotho, thereby attenuating production of membrane-bound and soluble αKlotho protein41. Therefore, αKLOTHO is a novel candidate gene for genetic hyperphosphatemia and calcinosis.

Emerging evidence in CKD and ESRD showed that kidney disease is a status of αKlotho deficiency. Although the mechanism of reduced circulating αKlotho is largely unclear, it is conceivable that αKlotho deficiency might be involved in the development of CKD-mineral bone disease (CKD-MBD): hyperphosphatemia, hyperparathyroidism, and vascular calcification. Hopefully αKlotho administration will be a novel strategy for CKD-MBD7, 42.

αKlotho overexpression

It is interesting to note that extremely high circulating αKlotho does not necessarily have better impact on mineral metabolism. In 2008, Brownstein and colleagues reported one case featuring hypophosphatemic rickets, hyperparathyroidism, >10-20 fold higher circulating αKlotho due to a balanced chromosomal translocation between 9q21.13 and 13q13.143. Unexpectedly, there were higher levels of circulating FGF23 and PTH which can trigger or exacerbate hypophosphatemia and osteodystrophy43. Up to now, the mechanism of αKlotho-induced elevation of these two phosphotropic hormones still has not been completely elucidated.

Similar phenotypic features were seen in mice with adenovirally delivered soluble αKlotho gene44. Mice had extremely high levels of circulating αKlotho (5 to 20-fold normal), and exhibited hypophosphatemia, hypocalcemia, reduced bone mineral content, expanded growth plates, and severe osteomalacia, and fracture. In addition, these mice had markedly elevated level of FGF23 (38 to 456-fold) in the circulation, and Fgf23 mRNA (>150 fold) in bone. Therefore, soluble αKlotho protein in very high levels potently stimulates FGF23 production through yet-to-be identified mechanism44.

Taken together, modulation of circulating αKlotho within a desired range is required for maintenance of phosphate balance to protect against phosphate toxicity. Both pathological increase and decrease in circulating αKlotho can cause disturbed phosphate homeostasis. Obviously, many clinical features in the patient with loss-of-function mutation in αKlotho gene41 and in the patient with gain-of-function translocation of αKlotho gene44 differ from those in αKlotho-deficient1 or αKlotho-overexpressing mice40, but the mechanism remains unexplained.

V体育安卓版 - αKlotho effect on Na-dependent phosphate cotransporters

External phosphate balance is achieved through modulation of intestinal uptake of phosphate from diet, and renal reabsorption of phosphate from urine via regulation of NaPi activity. Type II (SLCA34) and type III (SLC20) Na-coupled phosphate transporters are responsible for uptake of extracellular phosphate45, 46,47. The type II transporters NaPi-2a and NaPi-2c play a major role in phosphate reabsorption in the kidney through and NaPi-2b mediates phosphate absorption in the intestine . Type III cotransporters including PiT-1 and PiT-2 are expressed in more broad tissues. PiT-1 also exists in bone and kidney and PiT-2 in intestine and bone. They are assumed to participate in control of phosphate absorption in the intestine, phosphate reabsorption and excretion in the kidney, phosphate release and storage in the bone45-48 (Table 1). Note that both NaPi-II and III isoforms control phosphate influx across the apical membrane, but the mechanism of phosphate efflux across the basolateral membrane remains to be identified.

Table 1. Effect of αKlotho on Na-dependent phosphate cotransporters.

Isoforms Substrates Expression location αKlotho effect
Expression
abundance		 Transport
activity
NaPi-2a 3Na+/HPO42− Kidney: S1, 2, 3
Bone: osteoblast		 ↓
N/A		 ↓
N/A
NaPi-2b 3Na+/HPO42− Intestine: enterocytes in duodenum and
jejunum
Bone: only mRNA detected		 ↓

N/A		 ↓

N/A
NaPi-2c 2Na+/HPO42− Kidney: S1, S2 ↓ N/A
PiT-1 2Na+/H2PO4− Kidney: only mRNA detected
Intestine: enterocytes in duodenum and
jejunum
Bone: osteoblast
Artery: smooth muscle cell		 N/A
N/A

N/A
↓		 N/A
N/A

N/A
↓
PiT-2 2Na+/H2PO4− Kidney: S1, S2
Intestine: only mRNA detected
Bone: osteoblast with low abundance		 N/A
N/A
N/A		 N/A
N/A
N/A
Open in a new tab

"VSports手机版" αKlotho regulation of phosphate transport in the kidney

In the kidney, in addition to NaPi-2a and 2c whose expression pattern and function have been well characterized in proximal tubules, mRNA of both PiT-1 and PiT-2 was also detected, but only PiT-2 protein and function in proximal tubular epithelia was noted49, 50. After a high phosphate diet, rats showed marked increase in serum phosphate with gradual down-regulation of phosphate reabsorption mediated by decrease in NaPi-2a (< 1 hour) followed by delayed and eventual down-regulation of PiT-2 (> 8 hours) and NaPi-2c (> 24 hours)51 . NaPi-2a and NaPi-2c-mediated transport is suppressed by 32% and PiT2-mediated transport by 73%, with phosphate loading, which proves PiT-2 to be highly regulated at an intermediate time course between NaPi-2a and NaPi-2c51. The biological function of PiT-1 in the renal phosphate transport is uncharacterized.

αKlotho deficiency up-regulates, and αKlotho overexpression or supplementation down-regulates NaPi-2a expression in the kidney and NaPi transport activity (Figure 1)35, 39, 52. In addition, αKlotho deficiency is associated with up-regulation of NaPi-2c in the kidney54, which should exacerbate hyperphosphatemia in αKlotho-deficient mice.

Figure 1. αKlotho inhibits Na-dependent phosphate co-transporters.

Figure 1

Open in a new tab

Phosphate absorption from food is regulated by NaPi-2b and PiT-1 in small intestine, and phosphate reabsorption from urine by NaPi-2a, 2c and PiT-2 in renal proximal tubules. Gut and kidney are the two major organs to modulate phosphate excretion based on dietary intake and phosphate concentration in extracellular fluid, which is also maintained by phosphate trafficking across bone controlled by NaPi-2a and PiT-1 in osteoblast. Membrane αKlotho can regulate urinary phosphate excretion through FGF23 signaling pathway. In addition, soluble αKlotho can also exert phosphaturic action via a FGF23-independent manner to directly modulate NaPi-2a activity. The role of αKlotho in modulation of bone formation is known but αKlotho protein is not expressed in bone; soluble αKlotho is therefore considered an alternative candidate. How soluble αKlotho affects NaPi transport activity in the bone has not been addressed, although αKlotho has been shown to suppress NaPi-2a expression and activity in proximal tubules and PiT-1 expression and activity in vascular smooth muscle cells. Therefore, it is still premature to conclude that αKlotho can directly affect bone development and mineralization.

More interestingly, circulating soluble αKlotho can directly suppress NaPi transport activity, because αKlotho does so when directly added to cultured proximal tubule like cells, and in cell-free brush border membrane vesicles (BBMV) without FGF23. The fact that FGF23 null mice preserve the ability to increase urine phosphate excretion in response to soluble αKlotho35 further supports that αKlotho also has FGF23-independent pathway to induce phosphaturia. αKlotho appears to function as glycosidase acting on a yet unknown substrate in the brush border, since glucuronidase inhibitor can reverse αKlotho’s action on NaPi transport in both BBMV and cultured cells. Chronic effect of αKlotho on inhibition of NaPi-2a is associated with induction of NaPi-2a internalization and degradation through modification of moieties of sugar chain in NaPi-2a35. Thus far, mechanism of αKlotho effect on NaPi-2c is still completely elusive.

αKlotho effect on phosphate transport in the intestine

In the duodenum and jejunum, expression of NaPi-2b and both type III cotransporter isoforms ( PiT-1 and PiT-2) have been reported53, 54. In mice, the functional NaPi-2b, PiT-1 and PiT2 are also present in ileum55, but NaPi-2b and PiT-1 are thought to be most active in modulating intestinal phosphate absorption. In comparison with PiT-1, NaPi-2b is the major transporter that mediates phosphate absorption53 . The αKlotho-deficient mice displayed an increased activity of intestinal NaPi transport, and increased levels of NaPi-2b protein compared with WT mice52 , indicating that up-regulation of NaPi-2b protein and activity may be one of the molecular mechanisms of hyperphosphatemia in αKlotho-deficient mice. The fact that co-expression of αKlotho decreased phosphate-induced current in NaPi-2b-expressing Xenopus oocytes56 further supports that αKlotho directly down-regulates NaPi-2b activity (Figure 1). But the effect of αKlotho on PiT-1 in the intestine needs to be identified.

V体育安卓版 - αKlotho effect on the phosphate transport in the bone

Bone does not only provide mechanical support, but contributes to the maintenance of circulating phosphate and calcium as a target organ of several calciophosphotropic hormones such as 1,25-(OH)2 vitamin D, PTH, FGF23, and αKlotho, and as an organ producing FGF23.

There is high PiT-1 mRNA with low of PiT-2 mRNA abundance in osteoblasts57. Only PiT-1 rather PiT-2 mRNA was up-regulated by phosphate deprivation and Ca2+ treatment, which suggests that PiT-1 may play a more important role in phosphate trafficking across the bone58. Both NaPi-2a and NaPi-2b were recently found in osteoblast-like cell lines and play a role in phosphate flux to modulate mineralization59. But their responses to phosphate challenge differed, as phosphate supplementation only up-regulated NaPi-2a, and not NaPi-2b; whereas phosphate deprivation did not change either one. Whether these isoforms play distinct roles in phosphate trafficking across the bone individually, or in concert at different scenarios, remains to be explored.

The osteopenia in αKlotho-deficient mice has been recognized for more than one decade1, 60-62. However there is no αKlotho protein expression in the bone; soluble αKlotho may be, therefore, a contributor to maintenance of bone formation (Figure 1).

Conclusive remarks

Several lines of emerging evidence suggest that αKlotho deficiency and hyperphosphatemia are considered as risks for the high morbidity and mortality of cardiovascular diseases in CKD/ESRD7, 63-69. Therefore, the potential indication for αKlotho therapy will be genetic and acquired hyperphosphatemia such as CKD/ESRD. Better understanding of αKlotho physiology and pathophysiology will help to develop new drugs that may correct hyperphosphatemia and hypo-αKlotho-temia and to improve long-term outcome of CKD/ESRD patients.

Acknowledgments

The authors acknowledge grant support from the NIH (R01-DK091392, R01-DK092461), The George M. O’Brien Kidney Research Center at UT Southwestern Medical Center (P30-DK-07938), and, and the Charles and Jane Pak Research Foundation. Ao Bian was in part supported by Visiting Scholar Award from National Natural Science Foundation of China (81170660H0509, 81270408H0220), and Provincial Natural Science Foundation of Jiangsu, China (BK2011849). The authors thank Dr. Orson Moe for helpful discussions.

Footnotes

Conflict of interest

There are no conflicts of interest.

References

  • 1.Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51. doi: 10.1038/36285. [DOI] [PubMed] [Google Scholar]
  • 2.Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature genetics. 2000;26:345–348. doi: 10.1038/81664. [DOI] [PubMed] [Google Scholar]
  • 3.Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends in molecular medicine. 2006;12:298–305. doi: 10.1016/j.molmed.2006.05.002. [DOI] [PubMed] [Google Scholar]
  • 4.Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Current opinion in nephrology and hypertension. 2006;15:437–441. doi: 10.1097/01.mnh.0000232885.81142.83. [DOI] [PubMed] [Google Scholar]
  • 5.Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774. doi: 10.1038/nature05315. ["V体育ios版" DOI] [PubMed] [Google Scholar]
  • 6.Tan SJ, Smith ER, Hewitson TD, et al. The importance of klotho in phosphate metabolism and kidney disease. Nephrology. 2014 doi: 10.1111/nep.12268. [DOI] [PubMed] [Google Scholar]
  • 7.Olauson H, Larsson TE. FGF23 and Klotho in chronic kidney disease. Current opinion in nephrology and hypertension. 2013;22:397–404. doi: 10.1097/MNH.0b013e32836213ee. [DOI (VSports手机版)] [PubMed] [Google Scholar]
  • 8.Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contributions to nephrology. 2013;180:47–63. doi: 10.1159/000346778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Hu MC, Shiizaki K, Kuro-o M, et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annual review of physiology. 2013;75:503–533. doi: 10.1146/annurev-physiol-030212-183727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hu MC, Kuro-o M, Moe OW. Secreted klotho and chronic kidney disease. Advances in experimental medicine and biology. 2012;728:126–157. doi: 10.1007/978-1-4614-0887-1_9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kuro-o M. A potential link between phosphate and aging--lessons from Klotho-deficient mice. Mechanisms of ageing and development. 2010;131:270–275. doi: 10.1016/j.mad.2010.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nature reviews Endocrinology. 2012;8:276–286. doi: 10.1038/nrendo.2011.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nature reviews Endocrinology. 2009;5:611–619. doi: 10.1038/nrendo.2009.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Berner YN, Shike M. Consequences of phosphate imbalance. Annual review of nutrition. 1988;8:121–148. doi: 10.1146/annurev.nu.08.070188.001005. [DOI] [PubMed] [Google Scholar]
  • 15.Hu MC, Kuro-o M, Moe OW. Renal and extrarenal actions of Klotho. Seminars in nephrology. 2013;33:118–129. doi: 10.1016/j.semnephrol.2012.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Huang CL, Moe OW. Klotho: a novel regulator of calcium and phosphorus homeostasis. Pflugers Archiv : European journal of physiology. 2011;462:185–193. doi: 10.1007/s00424-011-0950-5. [DOI] [PubMed] [Google Scholar]
  • 17.Takenaka T, Watanabe Y, Inoue T, et al. Fibroblast growth factor 23 enhances renal klotho abundance. Pflugers Archiv : European journal of physiology. 2013;465:935–943. doi: 10.1007/s00424-013-1226-z. [DOI] [PubMed] [Google Scholar]
  • 18.Feng JQ, Ye L, Schiavi S. Do osteocytes contribute to phosphate homeostasis? Current opinion in nephrology and hypertension. 2009;18:285–291. doi: 10.1097/MNH.0b013e32832c224f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Feng JQ, Clinkenbeard EL, Yuan B, et al. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia. Bone. 2013;54:213–221. doi: 10.1016/j.bone.2013.01.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bonewald LF, Wacker MJ. FGF23 production by osteocytes. Pediatric nephrology (Berlin, Germany) 2013;28:563–568. doi: 10.1007/s00467-012-2309-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Experimental cell research. 2012;318:1040–1048. doi: 10.1016/j.yexcr.2012.02.027. ["VSports" DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113:561–568. doi: 10.1172/JCI19081. [V体育官网 - DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. American journal of physiology Renal physiology. 2005;289:F1088–1095. doi: 10.1152/ajprenal.00474.2004. [DOI] [PubMed] [Google Scholar]
  • 24.Gattineni J, Twombley K, Goetz R, et al. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. American journal of physiology Renal physiology. 2011;301:F371–377. doi: 10.1152/ajprenal.00740.2010. [DOI (VSports注册入口)] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gattineni J, Alphonse P, Zhang Q, et al. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. American journal of physiology Renal physiology. 2014;306:F351–358. doi: 10.1152/ajprenal.00232.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. The Journal of clinical investigation. 2007;117:4003–4008. doi: 10.1172/JCI32409. [V体育ios版 - DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kilav R, Silver J, Naveh-Many T. Parathyroid hormone gene expression in hypophosphatemic rats. The Journal of clinical investigation. 1995;96:327–333. doi: 10.1172/JCI118038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Naveh-Many T, Rahamimov R, Livni N, et al. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. The Journal of clinical investigation. 1995;96:1786–1793. doi: 10.1172/JCI118224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Gattineni J, Baum M. Genetic disorders of phosphate regulation. Pediatric nephrology (Berlin, Germany) 2012;27:1477–1487. doi: 10.1007/s00467-012-2103-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Forster IC, Hernando N, Biber J, et al. Proximal tubular handling of phosphate: A molecular perspective. Kidney international. 2006;70:1548–1559. doi: 10.1038/sj.ki.5001813. [DOI] [PubMed] [Google Scholar]
  • 31.Biber J, Hernando N, Forster I. Phosphate transporters and their function. Annual review of physiology. 2013;75:535–550. doi: 10.1146/annurev-physiol-030212-183748. [DOI (V体育官网)] [PubMed] [Google Scholar]
  • 32.Evenepoel P, Rodriguez M, Ketteler M. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Seminars in nephrology. 2014;34:151–163. doi: 10.1016/j.semnephrol.2014.02.007. [VSports app下载 - DOI] [PubMed] [Google Scholar]
  • 33.Lederer E. Regulation of Serum Phosphate. The Journal of physiology. 2014 doi: 10.1113/jphysiol.2014.273979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. Journal of the American Society of Nephrology : JASN. 2011;22:216–224. doi: 10.1681/ASN.2010020186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hu MC, Shi M, Zhang J, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2010;24:3438–3450. doi: 10.1096/fj.10-154765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. The Journal of biological chemistry. 2006;281:6120–6123. doi: 10.1074/jbc.C500457200. [DOI (VSports app下载)] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tsujikawa H, Kurotaki Y, Fujimori T, et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Molecular endocrinology (Baltimore, Md) 2003;17:2393–2403. doi: 10.1210/me.2003-0048. [DOI] [PubMed] [Google Scholar]
  • 38.Woudenberg-Vrenken TE, van der Eerden BC, van der Kemp AW, et al. Characterization of vitamin D-deficient klotho(−/−) mice: do increased levels of serum 1,25(OH)2D3 cause disturbed calcium and phosphate homeostasis in klotho(−/−) mice? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012;27:4061–4068. doi: 10.1093/ndt/gfs177. [DOI] [PubMed] [Google Scholar]
  • 39.Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2009;23:3702–3711. doi: 10.1096/fj.08-123992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science (New York, NY) 2005;309:1829–1833. doi: 10.1126/science.1112766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. The Journal of clinical investigation. 2007;117:2684–2691. doi: 10.1172/JCI31330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Drueke TB, Massy ZA. Circulating Klotho levels: clinical relevance and relationship with tissue Klotho expression. Kidney international. 2013;83:13–15. doi: 10.1038/ki.2012.370. [DOI] [PubMed] [Google Scholar]
  • 43.Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:3455–3460. doi: 10.1073/pnas.0712361105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Smith RC, O’Bryan LM, Farrow EG, et al. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. The Journal of clinical investigation. 2012;122:4710–4715. doi: 10.1172/JCI64986. [VSports - DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Werner A, Dehmelt L, Nalbant P. Na+-dependent phosphate cotransporters: the NaPi protein families. The Journal of experimental biology. 1998;201:3135–3142. doi: 10.1242/jeb.201.23.3135. ["VSports注册入口" DOI] [PubMed] [Google Scholar]
  • 46.Miyamoto K, Segawa H, Ito M, et al. Physiological regulation of renal sodium-dependent phosphate cotransporters. The Japanese journal of physiology. 2004;54:93–102. doi: 10.2170/jjphysiol.54.93. ["VSports注册入口" DOI] [PubMed] [Google Scholar]
  • 47.Sabbagh Y, Giral H, Caldas Y, et al. Intestinal phosphate transport. Advances in chronic kidney disease. 2011;18:85–90. doi: 10.1053/j.ackd.2010.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Forster IC, Hernando N, Biber J, et al. Phosphate transporters of the SLC20 and SLC34 families. Molecular aspects of medicine. 2013;34:386–395. doi: 10.1016/j.mam.2012.07.007. [DOI] [PubMed] [Google Scholar]
  • 49.Villa-Bellosta R, Sorribas V. Compensatory regulation of the sodium/phosphate cotransporters NaPi-IIc (SCL34A3) and Pit-2 (SLC20A2) during Pi deprivation and acidosis. Pflugers Archiv : European journal of physiology. 2010;459:499–508. doi: 10.1007/s00424-009-0746-z. [V体育官网入口 - DOI] [PubMed] [Google Scholar]
  • 50.Villa-Bellosta R, Ravera S, Sorribas V, et al. The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi. American journal of physiology Renal physiology. 2009;296:F691–699. doi: 10.1152/ajprenal.90623.2008. ["V体育官网入口" DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Moe OW. PiT-2 coming out of the pits. American journal of physiology Renal physiology. 2009;296:F689–690. doi: 10.1152/ajprenal.00007.2009. [DOI] [PubMed] [Google Scholar]
  • 52.Segawa H, Yamanaka S, Ohno Y, et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. American journal of physiology Renal physiology. 2007;292:F769–779. doi: 10.1152/ajprenal.00248.2006. [DOI] [PubMed] [Google Scholar]
  • 53.Giral H, Caldas Y, Sutherland E, et al. Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. American journal of physiology Renal physiology. 2009;297:F1466–1475. doi: 10.1152/ajprenal.00279.2009. [V体育ios版 - DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Bai L, Collins JF, Ghishan FK. Cloning and characterization of a type III Na-dependent phosphate cotransporter from mouse intestine. American journal of physiology Cell physiology. 2000;279:C1135–1143. doi: 10.1152/ajpcell.2000.279.4.C1135. [DOI] [PubMed] [Google Scholar]
  • 55.Marks J, Debnam ES, Unwin RJ. Phosphate homeostasis and the renal-gastrointestinal axis. American journal of physiology Renal physiology. 2010;299:F285–296. doi: 10.1152/ajprenal.00508.2009. [DOI (VSports手机版)] [PubMed] [Google Scholar]
  • 56.Dermaku-Sopjani M, Sopjani M, Saxena A, et al. Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2011;28:251–258. doi: 10.1159/000331737. [DOI] [PubMed] [Google Scholar]
  • 57.Nielsen LB, Pedersen FS, Pedersen L. Expression of type III sodium-dependent phosphate transporters/retroviral receptors mRNAs during osteoblast differentiation. Bone. 2001;28:160–166. doi: 10.1016/s8756-3282(00)00418-x. [DOI] [PubMed] [Google Scholar]
  • 58.Zoidis E, Ghirlanda-Keller C, Gosteli-Peter M, et al. Regulation of phosphate (Pi) transport and NaPi-III transporter (Pit-1) mRNA in rat osteoblasts. The Journal of endocrinology. 2004;181:531–540. doi: 10.1677/joe.0.1810531. [DOI (V体育安卓版)] [PubMed] [Google Scholar]
  • 59.Lundquist P, Murer H, Biber J. Type II Na+-Pi cotransporters in osteoblast mineral formation: regulation by inorganic phosphate. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007;19:43–56. doi: 10.1159/000099191. [DOI] [PubMed] [Google Scholar]
  • 60.Yamashita T, Nifuji A, Furuya K, et al. Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging. The Journal of endocrinology. 1998;159:1–8. doi: 10.1677/joe.0.1590001. ["V体育安卓版" DOI] [PubMed] [Google Scholar]
  • 61.Kawaguchi H, Manabe N, Miyaura C, et al. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. The Journal of clinical investigation. 1999;104:229–237. doi: 10.1172/JCI5705. [VSports注册入口 - DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Sasaki M, Hasegawa T, Yamada T, et al. Altered distribution of bone matrix proteins and defective bone mineralization in klotho-deficient mice. Bone. 2013;57:206–219. doi: 10.1016/j.bone.2013.08.008. [DOI (VSports在线直播)] [PubMed] [Google Scholar]
  • 63.Kim HR, Nam BY, Kim DW, et al. Circulating alpha-klotho levels in CKD and relationship to progression. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013;61:899–909. doi: 10.1053/j.ajkd.2013.01.024. [DOI (VSports最新版本)] [PubMed] [Google Scholar]
  • 64.Seiler S, Rogacev KS, Roth HJ, et al. Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2-4. Clinical journal of the American Society of Nephrology : CJASN. 2014;9:1049–1058. doi: 10.2215/CJN.07870713. [DOI (V体育官网入口)] [PMC free article] [PubMed] [Google Scholar]
  • 65.Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. Journal of the American Society of Nephrology : JASN. 2008;19:1092–1105. doi: 10.1681/ASN.2007070760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. Journal of the American Society of Nephrology : JASN. 2011;22:124–136. doi: 10.1681/ASN.2009121311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Yamada S, Tokumoto M, Tatsumoto N, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. American journal of physiology Renal physiology. 2014;306:F1418–1428. doi: 10.1152/ajprenal.00633.2013. [DOI] [PubMed] [Google Scholar]
  • 68.Kitagawa M, Sugiyama H, Morinaga H, et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PloS one. 2013;8:e56695. doi: 10.1371/journal.pone.0056695. [DOI (VSports手机版)] [PMC free article] [PubMed] [Google Scholar]
  • 69.Hu MC, Kuro-o M, Moe OW. alphaKlotho and vascular calcification: an evolving paradigm. Current opinion in nephrology and hypertension. 2014;23:331–339. doi: 10.1097/01.mnh.0000447024.97464.a3. ["V体育平台登录" DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES (VSports手机版)